We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$5.12B
1-Year Est. Return
314.02%
This Fund
S&P 500
This Quarter
Est. Return
+19.02%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$2.7B
AUM Growth
-$133M
(-4.7%)
Cap. Flow
-$358M
Cap. Flow
% of AUM
-13.27%
Top 10 Holdings %
Top 10 Hldgs %
54.24%
Holding
107
New
20
Increased
12
Reduced
35
Closed
22
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ascendis Pharma A/S
ASND
|
+$157M |
| 2 |
OMDA
Omada Health Inc
OMDA
|
+$42M |
| 3 |
Roivant Sciences
ROIV
|
+$36.1M |
| 4 |
CAI
Caris Life Sciences
CAI
|
+$29.6M |
| 5 |
Neurocrine Biosciences
NBIX
|
+$17.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$104M |
| 2 |
FOLD
Amicus Therapeutics
FOLD
|
+$90.7M |
| 3 |
SLNO
Soleno Therapeutics
SLNO
|
+$80.5M |
| 4 |
VRNA
Verona Pharma
VRNA
|
+$78.2M |
| 5 |
Iovance Biotherapeutics
IOVA
|
+$42.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Inhibikase Therapeutics
IKT
$331M
| $10.6M | 0.39% |
5,432,293
-492,707
| -8% | -$965K |
|
52
Viking Therapeutics
VKTX
$4.31B
| $10.1M | 0.37% |
380,700
-128,305
| -25% | -$3.38M |
|
53
Ultragenyx Pharmaceutical
RARE
$2.88B
| $9.82M | 0.36% |
+270,000
| New | +$9.73M |
|
54
Kymera Therapeutics
KYMR
$9.52B
| $9.17M | 0.34% |
+210,106
| New | +$7.23M |
|
55
Nautilus Biotechnolgy
NAUT
$221M
| $9.13M | 0.34% |
12,594,211
| – | – |
|
56
Penumbra
PEN
$12.5B
| $8.42M | 0.31% |
+32,797
| New | +$8.93M |
|
|
CBIO
57
Crescent Biopharma
CBIO
$407M
| $7.32M | 0.27% |
+453,686
| New | +$9.6M |
|
58
Aquestive Therapeutics
AQST
$517M
| $7.25M | 0.27% |
2,190,420
-1,536,788
| -41% | -$4.41M |
|
59
Janux Therapeutics
JANX
$992M
| $6.76M | 0.25% |
292,686
-677,726
| -70% | -$17.9M |
|
|
AVR
60
Anteris Technologies
AVR
$823M
| $6.46M | 0.24% |
1,705,130
-434,870
| -20% | -$1.77M |
|
61
PUT
Capricor Therapeutics
CAPR
$1.13B
| $6.45M | 0.24% |
+650,000
| New | +$6.87M |
|
62
Xenon Pharmaceuticals
XENE
$6.6B
| $6.28M | 0.23% |
200,791
-124,533
| -38% | -$4.06M |
|
63
Viridian Therapeutics
VRDN
$1.99B
| $6.26M | 0.23% |
447,507
-212,155
| -32% | -$2.88M |
|
64
Corvus Pharmaceuticals
CRVS
$1.25B
| $5.75M | 0.21% |
+1,438,595
| New | +$5.23M |
|
|
SEPN
65
Septerna Inc
SEPN
$1.51B
| $5.72M | 0.21% |
+541,450
| New | +$4.46M |
|
66
Globus Medical
GMED
$10.5B
| $5.22M | 0.19% |
+88,500
| New | +$5.72M |
|
|
NVNO
67
enVVeno Medical
NVNO
$7.2M
| $5.13M | 0.19% |
+36,713
| New | +$4.34M |
|
|
BBOT
68
BridgeBio Oncology
BBOT
$686M
| $4.23M | 0.16% |
398,000
| – | – |
|
|
IRD
69
Opus Genetics
IRD
$270M
| $4.07M | 0.15% |
4,325,000
| – | – |
|
|
CTNM
70
Contineum Therapeutics
CTNM
$532M
| $2.78M | 0.1% |
699,486
-741,763
| -51% | -$3.22M |
|
|
LYRA
71
DELISTED
LYRA THERAPEUTICS INC
LYRA
| $2.29M | 0.08% |
255,150
-1
| -0% | -$8 |
|
|
SCPH
72
DELISTED
scPharmaceuticals
SCPH
| $1.91M | 0.07% |
500,000
| – | – |
|
|
LONA
73
LeonaBio Inc
LONA
$67.8M
| $1.63M | 0.06% |
540,296
| – | – |
|
|
RAPT
74
DELISTED
RAPT Therapeutics
RAPT
| $1.47M | 0.05% |
183,890
-368,478
| -67% | -$2.81M |
|
|
TRIB
75
Trinity Biotech
TRIB
$6.79M
| $1.16M | 0.04% |
+1,790,000
| New | +$1.2M |
|
Similar funds
BG
TAM
CIA
AC
EIC
CIC
CS
NC
Perceptive Advisors's Q2 2025 Portfolio in Review
As of Q2 2025, Perceptive Advisors held 107 positions worth $2.7B, down 4.7% from $2.83B the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Perceptive Advisors withdrew a net $358M in Q2 2025, closing 22 positions and reducing 35 holdings. Its most notable exit was Intra-Cellular Therapies Inc., an estimated $104M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.
Against the trend, Perceptive Advisors opened a new position in Ascendis Pharma A/S worth $166M.
- Perceptive Advisors's largest Q2 2025 buy was Ascendis Pharma A/S: 963,886 shares worth $166M.
- Perceptive Advisors added most to Neurocrine Biosciences in Q2 2025, an estimated $17.8M increase.
- Perceptive Advisors's biggest Q2 2025 reduction was Amicus Therapeutics, cutting an estimated $90.7M.
- Perceptive Advisors fully exited Intra-Cellular Therapies Inc. in Q2 2025, selling an estimated $104M.
- Perceptive Advisors's ten largest holdings make up 54% of its $2.7B portfolio in Q2 2025.
- Perceptive Advisors opened 20 new positions and closed 22 in Q2 2025.
- Perceptive Advisors's portfolio value fell 4.7% quarter-over-quarter to $2.7B.
Based on Perceptive Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.